Palboxen

Palboxen is an orally bioavailable small molecule inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), developed and manufactured by Everest Pharmaceuticals as a generic version of palbociclib. It functions by binding to the ATP-binding site of CDK4 and CDK6, preventing the formation of the active kinase complex with D-type cyclins. This inhibition blocks the phosphorylation of the retinoblastoma (Rb) protein, which is a critical step for the cell cycle to progress from the G1 phase to the S phase. By inducing G1 cell cycle arrest, Palboxen effectively inhibits the proliferation of cancer cells, particularly in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. It is typically used in combination with endocrine therapies such as aromatase inhibitors or fulvestrant to overcome or delay resistance to hormonal treatment.

Brand names

Palboxen

Other names

palbociclib